No

Anabolic Steroid

Prophylactic use against hereditary angioedema

C-III

X

Nephrosis, carcinoma of breast or prostate, pregnancy, hypersensitivity to any component

May stunt bone growth in children; anabolic steroids may cause peliosis hepatis, liver cell tumors, and blood lipid changes with increased risk of arteriosclerosis; monitor diabetic patients carefully; use with caution in elderly patients, they may be at greater risk for prostatic hypertrophy; use with caution in patients with cardiac, renal, or hepatic disease or epilepsy

Male:

Postpubertal:

>10%:

Dermatologic: Acne

Endocrine & metabolic: Gynecomastia

Genitourinary: Bladder irritability, priapism

1% to 10%:

Central nervous system: Insomnia, chills

Endocrine & metabolic: Decreased libido, hepatic dysfunction

Gastrointestinal: Nausea, diarrhea

Genitourinary: Prostatic hypertrophy (elderly)

Hematologic: Iron deficiency anemia, suppression of clotting factors

<1%: Hepatic necrosis, hepatocellular carcinoma

Prepubertal:

>10%:

Dermatologic: Acne

Endocrine & metabolic: Virilism

1% to 10%:

Central nervous system: Chills, insomnia, factors

Dermatologic: Hyperpigmentation

Gastrointestinal: Diarrhea, nausea

Hematologic: Iron deficiency anemia, suppression of clotting

<1%: Hepatic necrosis, hepatocellular carcinoma

Female:

>10%: Endocrine & metabolic: Virilism

1% to 10%:

Central nervous system: Chills, insomnia

Endocrine & metabolic: Hypercalcemia

Gastrointestinal: Nausea, diarrhea

Hematologic: Iron deficiency anemia, suppression of clotting factors

Hepatic: Hepatic dysfunction

<1%: Hepatic necrosis, hepatocellular carcinoma

Increased toxicity: ACTH, adrenal steroids may increase risk of edema and acne; stanozolol enhances the hypoprothrombinemic effects of oral anticoagulants; enhances the hypoglycemic effects of insulin and sulfonylureas (oral hypoglycemics)

Synthetic testosterone derivative with similar androgenic and anabolic actions

Metabolism: In an analogous fashion to testosterone

Elimination: In an analogous fashion to testosterone

Children: Acute attacks:

<6 years: 1 mg/day

6-12 years: 2 mg/day

Adults: Oral: Initial: 2 mg 3 times/day, may then reduce to a maintenance dose of 2 mg/day or 2 mg every other day after 1-3 months

Dosing adjustment in hepatic impairment: Stanozolol is not recommended for patients with severe liver dysfunction

May cause insomnia

None reported

No information available to require special precautions

No effects or complications reported

Take as directed; do not exceed recommended dosage. Diabetics should monitor serum glucose closely and notify prescriber of changes; this medication can alter hypoglycemic requirements. You may experience decrease of libido or impotence (usually reversible); nausea, vomiting, or GI distress (frequent small meals, frequent mouth care, chewing gum, or sucking lozenges may help); or diarrhea (buttermilk, boiled milk, yogurt may help). Report persistent GI distress or diarrhea; change in color of urine or stool; unusual bruising, bleeding, or yellowing of eyes or skin; fluid retention (swelling of ankles, feet, or hands, difficulty breathing, or sudden weight gain); unresolved CNS changes (insomnia or chills); menstrual irregularity; excessive growth of body hair; or other adverse reactions. Pregnancy/breast-feeding precautions: Inform prescriber if you are pregnant. Do not get pregnant 1 month before, during, or for 1 month following therapy. Consult prescriber for instruction on appropriate contraceptive measures. This drug may cause severe fetal defects. Do not donate blood during or for 1 month following therapy (same reason). Do not breast-feed.

High protein, high caloric diet is suggested, restrict salt intake; glucose tolerance may be altered in diabetics

Tablet: 2 mg